TABLE 5.
Types of serious adverse events, their management and outcome among MDR/RR-TB patients started on STR in nine DR-TB centres of Nepal, 2018–2019
| Indicator | n | (%) |
|---|---|---|
| Total | 55 | (15.2) |
| Type | ||
| Hepatotoxicity | 20 | (36) |
| Ototoxicity | 19 | (35) |
| Hypokalaemia | 3 | (5) |
| Loss of vision | 2 | (4) |
| Psychiatric disorders | 2 | (4) |
| Hyperglycaemia | 2 | (4) |
| Allergy/hypersensitivity | 2 | (4) |
| Nephrotoxicity | 2 | (4) |
| Neurotoxicity | 1 | (2) |
| Cardiotoxicity | 1 | (2) |
| Hypothyroidism | 1 | (2) |
| Timing | ||
| <1 month | 7 | (13) |
| 1 month to end-intensive phase | 22 | (40) |
| Continuation phase | 11 | (20) |
| Missing | 15 | (27) |
| Management | ||
| Ancillary drugs only | 14 | (25) |
| Dose reduction | 3 | (5) |
| Temporary stop and re-challenge | 18 | (33) |
| Stop the drug permanently | 20 | (36) |
| Outcome | ||
| Resolved | 41 | (75) |
| Not resolved | 11 | (20) |
| Death | 3 | (5) |
MDR/RR-TB = multidrug-resistant/rifampicin-resistant TB; STR = shorter treatment regimen; DR-TB = drug-resistant TB.